Apidra, an insulin glulisine injection, received FDA approval in 2004. It is a rapid-acting insulin used to manage blood sugar levels in adults and children aged 4 years and older with diabetes [1].
What is Apidra's mechanism of action?
Apidra is a rapid-acting analog of human insulin. It works by lowering blood glucose by increasing glucose uptake by peripheral tissues, especially skeletal muscle and fat, and by decreasing hepatic glucose production. It also inhibits lipolysis in adipose tissue, inhibits proteolysis, and promotes protein synthesis [2].
When does Apidra's patent protection expire?
The primary patent for Apidra, U.S. Patent No. 5,750,583, was expected to expire in 2017 [3]. However, patent litigation and extensions can influence the actual market exclusivity. Information on specific patent expiry dates and any ongoing challenges can be found on DrugPatentWatch.com [3].
Can generic or biosimilar versions of Apidra be approved?
Generic versions of Apidra can be approved once patent exclusivity has expired or been invalidated. The pathway for approval of a generic rapid-acting insulin like Apidra is through an Abbreviated New Drug Application (ANDA) [4].
What is the difference between Apidra and other rapid-acting insulins?
Apidra is a rapid-acting insulin analog, meaning it is a modified version of human insulin designed to work faster and have a shorter duration of action compared to regular human insulin. It is generally administered before meals to control postprandial glucose levels. Other rapid-acting insulins include lispro (Humalog) and aspart (Novolog) [1, 5]. While all are rapid-acting, they have slight differences in their pharmacokinetic and pharmacodynamic profiles, which may lead to individual patient preferences [2, 5].